WallStreetZenWallStreetZen

NASDAQ: LFCR
Lifecore Biomedical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Should I buy or sell LFCR stock?

Based on 2 analysts offering ratings for Lifecore Biomedical Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their LFCR stock forecasts and price targets.

LFCR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-29
lockedlocked$00.00+00.00%2026-09-28

1 of 1

Forecast return on equity

Is LFCR forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is LFCR forecast to generate an efficient return on assets?

Company
N/A
Industry
22.36%

LFCR earnings per share forecast

What is LFCR's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.99
Avg 2 year Forecast
-$0.88
Avg 3 year Forecast
-$1.15

LFCR revenue forecast

What is LFCR's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$124.1M-6.63%
Avg 2 year Forecast
$133.2M+0.26%
Avg 3 year Forecast
$159.3M+19.9%
LFCR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LFCR revenue growth forecast

How is LFCR forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
0.09%
Industry
8.49%
Market
12.67%
LFCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LFCR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LFCR vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
LFCR$6.40N/AN/AHold
ACB$4.06N/AN/A
SIGA$3.04N/AN/A
BIOA$5.87$27.00+359.97%Strong Buy
CGC$0.65N/AN/A
View Top Pharmaceutical Stocks

Lifecore Biomedical Stock Forecast FAQ

Is Lifecore Biomedical Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: LFCR) stock is to Hold LFCR stock.

Out of 2 analysts, 0 (0%) are recommending LFCR as a Strong Buy, 0 (0%) are recommending LFCR as a Buy, 2 (100%) are recommending LFCR as a Hold, 0 (0%) are recommending LFCR as a Sell, and 0 (0%) are recommending LFCR as a Strong Sell.

If you're new to stock investing, here's how to buy Lifecore Biomedical stock.

What is LFCR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's current Earnings Per Share (EPS) is -$1.16. On average, analysts forecast that LFCR's EPS will be -$0.99 for 2026, with the lowest EPS forecast at -$1.03, and the highest EPS forecast at -$0.85. On average, analysts forecast that LFCR's EPS will be -$0.88 for 2027, with the lowest EPS forecast at -$1.06, and the highest EPS forecast at -$0.80. In 2028, LFCR's EPS is forecast to hit -$1.15 (min: -$1.11, max: -$1.19).

What is LFCR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: LFCR) forecast ROE is N/A, which is considered weak.

What is LFCR's earnings growth forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 15.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.55%.

Lifecore Biomedical's earnings in 2026 is -$43,188,000.On average, 7 Wall Street analysts forecast LFCR's earnings for 2026 to be -$37,376,111, with the lowest LFCR earnings forecast at -$38,950,799, and the highest LFCR earnings forecast at -$32,194,028. On average, 7 Wall Street analysts forecast LFCR's earnings for 2027 to be -$33,435,608, with the lowest LFCR earnings forecast at -$40,063,679, and the highest LFCR earnings forecast at -$30,206,742.

In 2028, LFCR is forecast to generate -$43,629,437 in earnings, with the lowest earnings forecast at -$41,918,479 and the highest earnings forecast at -$44,912,656.

What is LFCR's revenue growth forecast for 2026-2028?

(NASDAQ: LFCR) Lifecore Biomedical's forecast annual revenue growth rate of 0.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.67%.

Lifecore Biomedical's revenue in 2026 is $132,881,000.On average, 7 Wall Street analysts forecast LFCR's revenue for 2026 to be $4,696,429,154, with the lowest LFCR revenue forecast at $4,463,254,305, and the highest LFCR revenue forecast at $4,901,592,739. On average, 7 Wall Street analysts forecast LFCR's revenue for 2027 to be $5,043,163,184, with the lowest LFCR revenue forecast at $4,746,016,663, and the highest LFCR revenue forecast at $5,340,688,235.

In 2028, LFCR is forecast to generate $6,030,749,519 in revenue, with the lowest revenue forecast at $5,563,642,759 and the highest revenue forecast at $6,691,285,416.

What is LFCR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: LFCR) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 22.36%.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.